Difference between revisions of "Part:BBa K4165193"

(Usage and Biology)
(Usage and Biology)
Line 7: Line 7:
  
 
===Usage and Biology===
 
===Usage and Biology===
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 32 to 42.
+
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acids 32 to 42 of the fibril.
  
 
===<span class='h3bb'>Sequence and Features</span>===
 
===<span class='h3bb'>Sequence and Features</span>===

Revision as of 19:36, 11 October 2022


Amyloid beta peptide 13 (Aβ 32-42)

This part encodes a part of the Amyloid 𝛽 fragment (32-42) which has the ability to bind to A𝛽 plaques inside the brain.


Usage and Biology

Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acids 32 to 42 of the fibril.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Features and codon optimize

This sequence is optimized for E. coli bacteria

Source

Homo sapiens Amyloid-beta precursor protein - UniProt (P05067)


Dry lab

Modeling

Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model.

                             Figure 1.: Amyloid-beta (32-42) top model visualized by Pymol.


References

1- Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.